Works by KENTA MOTOMURA


Results: 33
    1
    2
    3

    A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma.

    Published in:
    Cancer Science, 2020, v. 111, n. 10, p. 3759, doi. 10.1111/cas.14582
    By:
    • Kudo, Masatoshi;
    • Morimoto, Manabu;
    • Moriguchi, Michihisa;
    • Izumi, Namiki;
    • Takayama, Tetsuji;
    • Yoshiji, Hitoshi;
    • Hino, Keisuke;
    • Oikawa, Takayoshi;
    • Chiba, Tetsuhiro;
    • Motomura, Kenta;
    • Kato, Junko;
    • Yasuchika, Kentaro;
    • Ido, Akio;
    • Sato, Takashi;
    • Nakashima, Daisuke;
    • Ueshima, Kazuomi;
    • Ikeda, Masafumi;
    • Okusaka, Takuji;
    • Tamura, Kazuo;
    • Furuse, Junji
    Publication type:
    Article
    4

    Kinetics of the hepatitis C virus during interferon therapy as a marker of therapeutic response.

    Published in:
    Journal of Gastroenterology & Hepatology, 2001, v. 16, n. 1, p. 29, doi. 10.1046/j.1440-1746.2001.02390.x
    By:
    • Nakamuta, M;
    • Nakamuta, Makoto;
    • Fukutomi, Takayoshi;
    • Shimohashi, Naoya;
    • Kinukawa, Naoko;
    • Uchimura, Koutaro;
    • Tada, Seiya;
    • Motomura, Kenta;
    • Enjoji, Munechika;
    • Kato, Masaki;
    • Iwamoto, Hiroaki;
    • Tanabe, Yuichi;
    • Imari, Yasuhisa;
    • Sakamoto, Shigeru;
    • Sakai, Hironori;
    • Nawata, Hajime
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.

    Published in:
    2020
    By:
    • Kudo, Masatoshi;
    • Okusaka, Takuji;
    • Motomura, Kenta;
    • Ohno, Izumi;
    • Morimoto, Manabu;
    • Seo, Satoru;
    • Wada, Yoshiyuki;
    • Sato, Shinpei;
    • Yamashita, Tatsuya;
    • Furukawa, Masayuki;
    • Aramaki, Takeshi;
    • Nadano, Seijin;
    • Ohkawa, Kazuyoshi;
    • Fujii, Hirofumi;
    • Kudo, Toshihiro;
    • Furuse, Junji;
    • Takai, Hiroki;
    • Homma, Gosuke;
    • Yoshikawa, Reigetsu;
    • Zhu, Andrew X.
    Publication type:
    journal article
    15

    Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2.

    Published in:
    Liver International, 2020, v. 40, n. 8, p. 2008, doi. 10.1111/liv.14462
    By:
    • Kudo, Masatoshi;
    • Galle, Peter R.;
    • Llovet, Josep M.;
    • Finn, Richard S.;
    • Vogel, Arndt;
    • Motomura, Kenta;
    • Assenat, Eric;
    • Merle, Philippe;
    • Brandi, Giovanni;
    • Daniele, Bruno;
    • Okusaka, Takuji;
    • Tomášek, Jiří;
    • Borg, Christophe;
    • Dadduzio, Vincenzo;
    • Morimoto, Manabu;
    • Pracht, Marc;
    • Jen, Min‐Hua;
    • Drove Ubreva, Nora;
    • Widau, Ryan C.;
    • Shinozaki, Kenta
    Publication type:
    Article
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33

    Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.

    Published in:
    Internal Medicine, 2022, v. 61, n. 21, p. 3157, doi. 10.2169/internalmedicine.9237-21
    By:
    • Rie Sugimoto;
    • Kenta Motomura;
    • Aritsune Ooho;
    • Yoshifusa Aratake;
    • Akihiro Ueda;
    • Takeshi Senju;
    • Yuki Tanaka;
    • Masayoshi Yada;
    • Kohsuke Tanaka;
    • Akifumi Kuwano;
    • Yuusuke Morita;
    • Shigehiro Nagasawa;
    • Mari Ooe;
    • Taiji Mutsuki;
    • Tsuyoshi Yoshimoto;
    • Naoki Yamashita;
    • Mai Nakashima;
    • Tomonobu Hioki;
    • Toshimasa Koyanagi;
    • Nobito Higuchi
    Publication type:
    Article